Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1
Maike Janssen(Heidelberg University), Sascha Dietrich(European Molecular Biology Organization), Peter‐Martin Bruch(European Molecular Biology Organization), Daniel Heid(Heidelberg University), George S. Vassiliou(Wellcome/MRC Cambridge Stem Cell Institute), Christoph Röllig(University Hospital Carl Gustav Carus), Martin Bornhäuser(Technische Universität Dresden), Carsten Müller‐Tidow(Heidelberg University), Claudia D. Baldus(University Hospital Schleswig-Holstein), Maximilian Felix Blank(Heidelberg University), Simon Renders(Heidelberg Institute for Stem Cell Technology and Experimental Medicine), Katharina Weidenauer(Heidelberg University), Birgit Besenbeck(Heidelberg University), Friedrich Stölzel(German Cancer Research Center), Anne K. Ludwig(Technical University of Darmstadt), Richard F. Schlenk(German Cancer Research Center), Binje Vick(Helmholtz Zentrum München), Alexander Waclawiczek(German Cancer Research Center), Margarete A. Fabre(AstraZeneca (United Kingdom)), Muxin Gu(Wellcome/MRC Cambridge Stem Cell Institute), Christina Schmidt(Heidelberg University), Irmela Jeremias(Helmholtz Zentrum München), Christian Rohde(Heidelberg University), Carolin Kolb(Heidelberg University), Stefanie Göllner(Heidelberg University), Uwe Platzbecker(National Center for Tumor Diseases), Simon Raffel(Heidelberg University), Andreas Trumpp(German Cancer Research Center), Hubert Serve(Goethe University Frankfurt), Lisa Vierbaum(Heidelberg University), Jeroen Krijgsveld(German Cancer Research Center), Tim Sauer(Heidelberg University), Adriana Przybylla(German Cancer Research Center), Sophie A. Herbst(German Cancer Research Center), Mareike Knoll(Heidelberg University), Caroline Pabst(European Molecular Biology Organization)
Cited by 100
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
|The Lancet|2005|3.4k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k